SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS, and recent preclinical studies have demonstrated that combining KRAS and EGFR inhibitors with SOS1 inhibitors can overcome ...
The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback